Encapsulated FMT
Phase 3Small molecule
Encapsulated FMT is one of 50 small molecule programs targeting Cirrhosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
74 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Xifaxan
SSalix
Approved
Zocor
OOrganon and Co
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Chronulac
SSolvay Pharmaceuticals
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Esmeron
FFresenius Kabi USA, LLC
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Bumex
VValidus Pharmaceuticals
Phase 3
Crestor
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Encapsulated FMT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKing's College London